Report cover image

Respiratory Syncytial Virus Vaccine for the Elderly Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 123 Pages
SKU # APRC20260642

Description

Summary

According to APO Research, the global Respiratory Syncytial Virus Vaccine for the Elderly market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly include GSK, Icosavax, Moderna, Pfizer, RNAimmune, Sanofi, Advaccine, Daiichi Sankyo and Immorna, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Respiratory Syncytial Virus Vaccine for the Elderly, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Syncytial Virus Vaccine for the Elderly.

The report will help the Respiratory Syncytial Virus Vaccine for the Elderly manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Respiratory Syncytial Virus Vaccine for the Elderly market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Respiratory Syncytial Virus Vaccine for the Elderly market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Company

GSK
Icosavax
Moderna
Pfizer
RNAimmune
Sanofi
Advaccine
Daiichi Sankyo
Immorna
Blue Lake Biotechnology
Clover Biopharma
Innorna
Starna Therapeutics
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type

Recombinant Protein Vaccine
Nucleic Acid Vaccines
Others
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application

Hospital
Centers for Disease Control and Prevention
Others
Respiratory Syncytial Virus Vaccine for the Elderly Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for the Elderly market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for the Elderly and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for the Elderly.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Respiratory Syncytial Virus Vaccine for the Elderly by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Respiratory Syncytial Virus Vaccine for the Elderly in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

123 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size (2020-2031)
2.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2020-2031)
2.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Average Price (2020-2031)
2.3 Respiratory Syncytial Virus Vaccine for the Elderly by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Recombinant Protein Vaccine
2.3.3 Nucleic Acid Vaccines
2.3.4 Others
2.4 Respiratory Syncytial Virus Vaccine for the Elderly by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital
2.4.3 Centers for Disease Control and Prevention
2.4.4 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units) of Manufacturers (2020-2025)
3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue of Manufacturers (2020-2025)
3.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Average Price by Manufacturers (2020-2025)
3.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Product Type & Application
3.8 Global Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Established Date
3.9 Global Respiratory Syncytial Virus Vaccine for the Elderly Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 GSK
4.1.1 GSK Company Information
4.1.2 GSK Business Overview
4.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.1.5 GSK Recent Developments
4.2 Icosavax
4.2.1 Icosavax Company Information
4.2.2 Icosavax Business Overview
4.2.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.2.5 Icosavax Recent Developments
4.3 Moderna
4.3.1 Moderna Company Information
4.3.2 Moderna Business Overview
4.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.3.5 Moderna Recent Developments
4.4 Pfizer
4.4.1 Pfizer Company Information
4.4.2 Pfizer Business Overview
4.4.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.4.5 Pfizer Recent Developments
4.5 RNAimmune
4.5.1 RNAimmune Company Information
4.5.2 RNAimmune Business Overview
4.5.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.5.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.5.5 RNAimmune Recent Developments
4.6 Sanofi
4.6.1 Sanofi Company Information
4.6.2 Sanofi Business Overview
4.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.6.5 Sanofi Recent Developments
4.7 Advaccine
4.7.1 Advaccine Company Information
4.7.2 Advaccine Business Overview
4.7.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.7.5 Advaccine Recent Developments
4.8 Daiichi Sankyo
4.8.1 Daiichi Sankyo Company Information
4.8.2 Daiichi Sankyo Business Overview
4.8.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.8.5 Daiichi Sankyo Recent Developments
4.9 Immorna
4.9.1 Immorna Company Information
4.9.2 Immorna Business Overview
4.9.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.9.5 Immorna Recent Developments
4.10 Blue Lake Biotechnology
4.10.1 Blue Lake Biotechnology Company Information
4.10.2 Blue Lake Biotechnology Business Overview
4.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.10.5 Blue Lake Biotechnology Recent Developments
4.11 Clover Biopharma
4.11.1 Clover Biopharma Company Information
4.11.2 Clover Biopharma Business Overview
4.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.11.5 Clover Biopharma Recent Developments
4.12 Innorna
4.12.1 Innorna Company Information
4.12.2 Innorna Business Overview
4.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.12.5 Innorna Recent Developments
4.13 Starna Therapeutics
4.13.1 Starna Therapeutics Company Information
4.13.2 Starna Therapeutics Business Overview
4.13.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
4.13.5 Starna Therapeutics Recent Developments
5 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Scenario by Region
5.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2020-2031
5.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2020-2025
5.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2026-2031
5.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2020-2031
5.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2020-2025
5.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2026-2031
5.4 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
5.4.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
5.4.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
5.5.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
5.5.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
5.6.1 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
5.6.3 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
5.7.1 South America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
5.7.3 South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
5.8.1 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2020-2031)
5.8.3 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2020-2031)
6.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2020-2031) & (Units)
6.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2020-2031)
6.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2020-2031)
6.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2020-2031)
6.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2020-2031)
7 Segment by Application
7.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2020-2031)
7.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2020-2031) & (Units)
7.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2020-2031)
7.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2020-2031)
7.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2020-2031)
7.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Analysis
8.1.1 Respiratory Syncytial Virus Vaccine for the Elderly Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process
8.2 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
8.2.3 Respiratory Syncytial Virus Vaccine for the Elderly Customers
9 Global Respiratory Syncytial Virus Vaccine for the Elderly Analyzing Market Dynamics
9.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends
9.2 Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers
9.3 Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges
9.4 Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.